Customize your JAMA Network experience by selecting one or more topics from the list below.
On August 27, 1999, Merck Vaccine Division* (Merck & Co., Inc., West Point, Pennsylvania) received approval from the Food and Drug Administration (FDA) of a supplement to Merck's license application to include the manufacture of single-antigen preservative-free hepatitis B vaccine (Recombivax HB®, Pediatric); distribution is expected to begin September 13, 1999. In addition, SmithKline Beecham Biologicals (SmithKline Beecham, Philadelphia, Pennsylvania), expects to make single-antigen preservative-free hepatitis B vaccine (Engerix-B®, Pediatric) available in the near future. Further product information will be provided when it becomes available. Product packaging and labels will indicate that these vaccines do not contain preservative.
Availability of Hepatitis B Vaccine That Does Not Contain Thimerosal as a Preservative. JAMA. 1999;282(13):1219–1220. doi:10.1001/jama.282.13.1219
Create a personal account or sign in to: